The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

Journal of Clinical Investigation

Volumn 112, Issue 1, 2003, Pages 91-100

  Xu, Aimin ^a,b   Wang, Yu ^a   Keshaw, Hussila ^a   Xu, Lance Yi ^a   Lam, Karen S L ^b   Cooper, Garth J S ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALCOHOL; CARNITINE PALMITOYLTRANSFERASE; CYTOKINE; FATTY ACID SYNTHASE; INSULIN; RECOMBINANT ADIPONECTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FATTY ACID; PROTEIN; RECOMBINANT PROTEIN; SIGNAL PEPTIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT INTAKE; FATTY ACID OXIDATION; FATTY LIVER; HEPATOMEGALY; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; LIVER DISEASE; LIVER FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; ALCOHOLIC FATTY LIVER; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; LIVER; MALE; METABOLISM; MORBID OBESITY; OXIDATION REDUCTION REACTION;

ADIPONECTIN; ALANINE TRANSAMINASE; ANIMALS; FATTY ACIDS; FATTY LIVER; FATTY LIVER, ALCOHOLIC; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY, MORBID; OXIDATION-REDUCTION; PROTEINS; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0041302377     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317797     Document Type: Article

References (65)

1. Diehl, A.M. 2002. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am. J. Physiol. 282:G1-G5.
2. Molina, P.E., et al. 2002. Molecular pathology and clinical aspects of alcohol-induced tissue injury. Alcohol. Clin. Exp. Res. 26:120-128.
3. Stewart, S., Jones, D., and Day, C.P. 2001. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol. Med. 7:408-413.
4. Diehl, A.M. 2000. Cytokine regulation of liver injury and repair. Immunol. Rev. 174:160-171.
5. Tilg, H., and Diehl, A.M. 2000. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343:1467-1476.
6. Thurman, R.G., et al. 1999. Mechanisms of alcohol-induced hepatotoxicity: studies in rats. Front. Biosci. 4:e42-e46.
7. McClain, C.J., et al. 1999. Cytokines in alcoholic liver disease. Semin. Liver Dis. 19:205-219.
8. Adachi, Y., et al. 1994. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology. 20:453-460.
9. Jarvelainen, H.A., et al. 2000. Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. J. Hepatol. 32:900-910.
10. Iimuro, Y., et al. 1997. Antibodies to tumor necrosis factor alpha attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 26:1530-1537.
11. Yin, M., et al. 1999. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology. 117:942-952.
12. Enomoto, N., et al. 2002. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology. 123:291-300.
13. Hill, D.B., et al. 2002. A role for interleukin-10 in alcohol-induced liver sensitization to bacterial lipopolysaccharide. Alcohol. Clin. Exp. Res. 26:74-82.
14. Brunt, E.M. 2001. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 21:3-16.
15. Matteoni, C.A., et al. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116:1413-1419.
16. Li, Z., et al. 2003. Probiotics and antibodies to TNFα inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 37:343-350.
17. Berg, A.H., Combs, T.P., and Scherer, P.E. 2002. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 13:84-89.
18. Shapiro, L., and Scherer, P.E. 1998. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 8:335-338.
19. Maeda, N., et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8:731-737.
20. Yamauchi, T., et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7:941-946.
21. Fruebis, J., et al. 2001. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Nat. Acad. Sci. U. S. A. 98:2005-2010.
22. Berg, A.H., et al. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947-953.
23. Wang, Y., Xu, A., Knight, C., Xu, L.Y., and Cooper, G.J. 2002. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J. Biol. Chem. 277:19521-19529.
24. Yokota, T., et al. 2000. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 96:1723-1732.
25. Lindros, K.O., and Jarvelainen, H.A. 1998. A new oral low-carbohydrate alcohol liquid diet producing liver lesions: a preliminary account. Alcohol Alcohol. 33:347-353.
26. Piot, C., et al. 1999. Effects of dietary coconut oil on fatty acid oxidation capacity of the liver, the heart and skeletal muscles in the preruminant calf. Br. J. Nutr. 82:299-308.
27. Adamo, S., et al. 1988. Effect of L-carnitine on ethanol and acetate plasma levels after oral administration of ethanol in humans. Alcohol. Clin. Exp. Res. 12:653-654.
28. Guzman, M., and Castro, J. 1989. Ethanol increases the sensitivity of carnitine palmitoyltransferase I to inhibition by malonyl-CoA in short-term hepatocyte incubations. Biochim. Biophys. Acta. 1002:405-408.
29. Chang, H.C., et al. 1967. Liver acetyl CoA carboxylase and fatty acid synthetase: relative activities in the normal state and in hereditary obesity. Biochem. Biophys. Res. Commun. 28:682-686.
30. Bijleveld, C., and Geelen, M.J. 1987. Measurement of acetyl-CoA carboxylase activity in isolated hepatocytes. Biochim. Biophys. Acta. 918:274-283.
31. Kudo, N., et al. 1996. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim. Biophys. Acta. 1301:67-75.
32. Burant, C.F., et al. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:2900-2908.
33. Baraona, E., and Lieber, C.S. 1979. Effects of ethanol on lipid metabolism. J. Lipid Res. 20:289-315.
34. Eaton, S., Record, C.O., and Bartlett, K. 1997. Multiple biochemical effects in the pathogenesis of alcoholic fatty liver. Eur. J. Clin. Invest. 27:719-722.
35. Guzman, M., and Geelen, M.J. 1988. Effects of ethanol feeding on the activity and regulation of hepatic carnitine palmitoyltransferase I. Arch. Biochem. Biophys. 267:580-588.
36. Guzman, M., and Geelen, M.J. 1988. Short-term inhibition of carnitine palmitoyltransferase I activity in rat hepatocytes incubated with ethanol. Biochem. Biophys. Res. Commun. 154:682-687.
37. Siler, S.Q., Neese, R.A., and Hellerstein, M.K. 1999. De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am. J. Clin. Nutr. 70:928-936.
38. You, M., Fischer, M., Deeg, M.A., and Crabb, D.W. 2002. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J. Biol. Chem. 277:29342-29347.
39. Chitturi, S., et al. 2002. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 35:373-379.
40. Lin, H.Z., et al. 2000. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6:998-1003.
41. Kubota, N., et al. 2002. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol Chem. 277:35863-35866.
42. Campfield, L.A., Smith, F.J., and Burn, P. 1996. The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks. Horm. Metab. Res. 28:619-632.
43. Hu, E., Liang, P., and Spiegelman, B.M. 1996. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271:10697-10703.
44. Yamauchi, T., et al. 2003. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 278:2461-2468.
45. Wanless, I.R., and Lentz, J.S. 1990. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 12:1106-1110.
46. Hotta, K., et al. 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20:1595-1599.
47. Hotta, K., et al. 2001. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 50:1126-1133.
48. Lin, H.Z., Yang, S.Q., Zeldin, G., and Diehl, A.M. 1998. Chronic ethanol consumption induces the production of tumor necrosis factor-alpha and related cytokines in liver and adipose tissue. Alcohol. Clin. Exp. Res. 22(Suppl.):231S-237S.
49. Fasshauer, M., et al. 2002. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 290:1084-1089.
50. Wilkes, J.J., DeForrest, L.L., and Nagy, L.E. 1996. Chronic ethanol feeding in a high-fat diet decreases insulin-stimulated glucose transport in rat adipocytes. Am. J. Physiol. 271:E477-E484.
51. Delporte, M.L., et al. 2002. Pre- and posttranslational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem. J. 367:677-685.
52. Fasshauer, M., et al. 2001. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 507:142-146.
53. Steppan, C.M., and Lazar, M.A. 2002. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 13:18-23.
54. Ouchi, N., et al. 2001. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 103:1057-1063.
55. Ouchi, N., et al. 1999. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 100:2473-2476.
56. Ross, R. 1999. Atherosclerosis: an inflammatory disease. New. Engl. J. Med. 340:115-126.
57. Combs, T.P., et al. 2001. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108:1875-1881.
58. Yamauchi, T., et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 8:1288-1295.
59. Winder, W.W., and Hardie, D.G. 1999. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277:E1-E10.
60. Chitturi, S., and Farrell, G.C. 2001. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21:27-41.
61. Falck-Ytter, Y., et al. 2001. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin. Liver Dis. 21:17-26.
62. Marceau, P., et al. 1999. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab. 84:1513-1517.
63. Marchesini, G., et al. 2001. Metformin in non-alcoholic steatohepatitis. Lancet. 358:893-894.
64. Funabiki, A., et al. 2002. Adiponectin is associated with insulin resistance in liver. Diabetes. 51(Suppl. 2):32a. (Abstr.)
65. Yoda-Murakami, et al. 2001. Change in expression of GBP28/adiponectin in carbon retrachloride-administrated mouse liver. Biochem. Biophys. Res. Commun. 285:372-377.